Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 21, 2025Open Access

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJohn T. PhoenixABAudris BudreikaDSDevin A Schmeck

Discussion

Loading...

Member takes

Overview

Research reveals SOX2 engages FOXA1 to enhance resistance in prostate cancer, suggesting a new therapeutic approach.

Key Points

  • MAIN FINDING: SOX2 and FOXA1 work together to promote cell cycle progression in therapy-resistant prostate cancer.
  • KEY EVIDENCE: Their interaction aids in lineage plasticity, contributing to the aggressive neuroendocrine prostate cancer subtype.
  • APPROACH: The study investigates the physical binding and regulatory role of these transcription factors in advanced prostate cancers.
  • SIGNIFICANCE: Targeting the SOX2/FOXA1 partnership may offer innovative treatments for patients with late-stage prostate cancer.

Cite This Study

Phoenix et al. (2025) studied this question.

synapsesocial.com/papers/689a02c9e6551bb0af8cd024https://doi.org/10.1101/2025.07.18.664790
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies2024 · 52 citations
  2. 2Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy2012 · 4,636 citations
  3. 3Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression2022 · 100 citations
  4. 4Autonomous action and cooperativity between the ONECUT2 transcription factor and its 3′ untranslated region2023 · 4 citations
  5. 5Cooperative DNA Recognition Modulated by an Interplay between Protein-Protein Interactions and DNA-Mediated Allostery2015 · 31 citations